Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company focused on helping patients who suffer from severe respiratory diseases to breathe better and live life more fully. The company is being purpose-built using our proprietary nitric oxide platform technology. These preclinical assets are licensed from Novan (NASDAQ:NOVN) and were developed in collaboration with Dr. Mark Schoenfisch’s lab at UNC Chapel Hill.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.